Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -7.26
- Piotroski Score 5.00
- Grade Neutral
- Symbol (AVRO)
- Company AVROBIO, Inc.
- Price $1.40
- Changes Percentage (-1.41%)
- Change -$0.02
- Day Low $1.38
- Day High $1.44
- Year High $19.80
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 08/07/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.69
- Trailing P/E Ratio 2.2
- Forward P/E Ratio 2.2
- P/E Growth 2.2
- Net Income $12.16 M
Income Statement
Quarterly
Annual
Latest News of AVRO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Tectonic bets on GPCR heart failure drug following reverse merger with Avrobio
Tectonic Therapeutic completes reverse merger with Avrobio, now trading on Nasdaq as Tectonic Therapeutic (TECX). The new company raised $130.7m in a private placement, ensuring cash reserves of $181m...
By Yahoo! Finance | 4 months ago -
Russia's Lavrov to visit China to discuss Ukraine war
MOSCOW (Reuters) - Russian Foreign Minister Sergei Lavrov will visit China on Monday and Tuesday to discuss the war in Ukraine and the deepening partnership between Moscow and Beijing. Talks betwe...
By Reuters | 7 months ago -
Brazil's Lula to meet Russia's Lavrov on Thursday
BRASILIA (Reuters) - Brazilian President Luiz Inacio Lula da Silva is set to meet with Russian Foreign Minister Sergei Lavrov on Thursday in Brasilia, according to the president's office, which sa...
By Reuters | 8 months ago
